Latest News

 Filter by Provider

Lyft needs to consistently maintain growth rates that are similar to or better than Uber's to keep up with the S&P 500 in the long run.

BJ's doesn't offer much in the way of growth, whereas TJX is more appealing for the long term.

Although Palantir's stock has looked unstoppable in recent years, that doesn't mean it will keep going up forever.

Reflecting on his acting role in the 2019 film 'Uncut Gems', Kevin O'Leary said growth only happens when you are willing to get uncomfortable.

It took many years, but Japan’s bond market has finally gone non-insane.

Growth stocks are still in favor and even though many have had big rallies in 2025, that doesn’t mean there isn’t more upside expected for 2026.

Silver price rallies to a new all-time high of $67.46 even though US Treasury yields and the US Dollar remain firm on Friday.

Medtronic's (NYSE: MDT) diabetes unit, MiniMed Group, filed for a U.S. initial public offering (IPO) on Friday.

B&T Capital Ramps Up AESI Holdings With Additional 306K Shares

Tesla stock blasted higher on news about the company's robotaxi.

Silver is in a historic breakout and leading gold and miners but is short-term extended. A brief holiday pullback is possible before the next leg higher toward much larger upside targets as the long-term bull trend remains firmly intact.

These tech giants are already massive, but that doesn't mean they've run out of opportunities to grow.

B & T Capital Scoops Up 105K Shares of IGF in Infrastructure Play

Starbucks Corp. (NASDAQ: SBUX) on Friday named Amazon veteran Anand Varadarajan its new chief technology officer, starting Jan. 19.

After a tough stretch for REITs, Resolution Capital’s entry into Healthcare Realty Trust highlights a view that valuation and cash flow matter more than near-term rate debates

Republican consumer sentiment remains notably more optimistic than overall or Democratic sentiment in the latest University of Michigan survey, a pattern that has persisted with only slight erosion and stands apart from broader expectations data.

A meme stock rally doesn't suddenly make Kohl's a good stock to buy.

AEGIS Doubles Down on Vermillion Energy (VET), Should You Invest?

The Flywire stake represents 10.02% of AUM, making it the fund’s 4th-largest holding.

Investors have 865 million reason to celebrate.

The voice AI solutions provider has a bright future despite a turbulent 2024.

This stock is a Dividend King, and its 4.9% yield has never been this high.

A three-week options update shows how time decay can work for or against you: a GILD diagonal spread thrives on positive decay while VLO and XOM struggle. The key lesson is how trade structure often matters more than direction.

Curious about Progressive's stock potential? Our experts break down the ratings and insights that could shape your investment decisions for 2025.

The company has quite an interesting asset in its portfolio.

Record profits prompted the cruise ship operator to reinstate its dividend.

The Invesco QQQ Trust has been one of the best ETFs on the market.

Which of these little altcoins has a brighter future?

There has been a lot of chatter about selling in the Magnificent Seven Stocks (Mag Seven) and redeployment or rotation into the

These five companies come with above-average yields and buy ratings from Wall Street analysts.

The gold and silver mining group has been en fuego this year and a good number of analysts expect that to continue in 2026.

The data center developer announced new funding right as an AI rally kicked off.

Shares in the package delivery giant may be surging higher this holiday season, but renewed worries could emerge next year.

The company said that it has secured work for a potentially globe-spanning project in the defense field.

Meta said in a filing with the Securities and Exchange Commission that Powell McCormick notified the company on Friday that she will resign effective immediately.

The ruling lifts a legal overhang that had clouded Musk’s incentives as Tesla leans further into AI and self-driving ambitions.

The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.

More capital is coming to the ledger.

Mag 7 members are expected to see 16.9% earnings growth on 16.4% higher sales in Q4.

An analyst bumped his price target higher on the company.

We discuss what’s actually driving crypto markets beneath the headlines.

CoreWeave shares roared back to life today.

Today, Dec. 19, 2025, investors are weighing record cruise profits, a revived payout, and fresh guidance for the next cycle.

If the United States wants to stay competitive, we need to treat mineral processing as a national priority. Because the Genesis Mission won’t matter if we can’t secure access to these critical materials.